• The scale of the need for neurological solutions is enormous; the World Health Organization reports that more than three billion people live with a neurological condition.
  • Quantum focuses on neurodegenerative, metabolic and alcohol misuse disorders, pursuing a strategy that pairs pharmaceutical research with commercialization partnerships and licensing structures designed to support multiple potential revenue streams.
  • The most advanced piece of the neurodegenerative strategy is Lucid-MS, a patented new chemical entity designed to address demyelination.

LOS ANGELES, CA - November 5, 2026 (NEWMEDIAWIRE) - Brain disorders touch more lives than almost any other area of medicine, yet they remain among the hardest to treat. Quantum BioPharma (NASDAQ: QNTM) is taking on that challenge with a diversified strategy that spans clinical drug development, consumer wellness and royalty-based partnerships.

The scale of the need is enormous. The World Health Organization reported that more than three billion people were living with a neurological condition in 2021. The overall burden of disability, illness and premature death from these conditions rose…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.

View the original release on www.newmediawire.com